This study was designed to evaluate the clinical relevance of the SNP rs11212617 C allele with respect to its potential to predict a pCR in breast cancer patients with HER2 overexpression treated with metformin-containing neoadjuvant systemic therapy (Figure 1). Here, ERBB2 is linked to breast carcinoma.